Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Hepatitis C

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 38 articles: HTML format

Single Articles

July 2025
1. VO-QUANG E, Rodriguez C, Ly A, Ndow G, et al
   Virological tools fail to properly identify "unusual" hepatitis C virus subtypes resistant to direct-acting antiviral drugs in The Gambia.
   J Infect Dis. 2025 Jul 22:jiaf378. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2025
2. WEGERMANN K, Lucas JE, Dubois L, Mangus R, et al
   Plasma lipid metabolites differentiate metabolic from viral chronic liver disease.
   J Infect Dis. 2025 May 23:jiaf270. doi: 10.1093.
   PubMed     Abstract available
   
   
   
3. GRANTZ KH, Anantharam R, Kandathil AJ, Quinn J, et al
   Multiple approaches to genetic sequencing to identify hepatitis C virus reinfection among people who inject drugs.
   J Infect Dis. 2025 May 15:jiaf235. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2025
4. GONZALEZ-SERNA A, Corma-Gomez A, Cano M, Ricardo RS, et al
   Influence of Cellular Aging on Liver Stiffness in HCV Patients Achieving Sustained Viral Response.
   J Infect Dis. 2025 Feb 19:jiaf087. doi: 10.1093.
   PubMed     Abstract available
   
   
   December 2024
5. WANG J, Genberg BL, Feder K, Kirk GD, et al
   Impact of pandemic-induced service disruptions and behavioral changes on HCV and HIV transmission amongst people who inject drugs: a modeling study.
   J Infect Dis. 2024 Dec 6:jiae599. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. SACHITHANANDHAM J, Leep-Lazar J, Quinn J, Bowden K, et al
   Direct acting antivirals eradicate HCV from the liver quickly in people with HIV but do not fully reverse immune activation.
   J Infect Dis. 2024 Dec 4:jiae598. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2024
7. TRUSCELLO E, Wang S, Young J, Sebastiani G, et al
   Changes in hepatic steatosis before and after direct acting antiviral treatment in people living with HIV and Hepatitis C coinfection.
   J Infect Dis. 2024 Oct 17:jiae487. doi: 10.1093.
   PubMed     Abstract available
   
   
   May 2024
8. GRUDDA T, Thomas DL, Kirk GD, Mehta SH, et al
   Hepatitis B virus DNA and RNA persist in liver after serologic recovery in persons with hepatitis C virus.
   J Infect Dis. 2024 May 23:jiae248. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. MBISA JL, Lapp Z, Bibby DF, Phillips LT, et al
   Identification of two novel subtypes of hepatitis C virus genotype 8 and a potential new genotype successfully treated with direct acting antivirals.
   J Infect Dis. 2024 May 8:jiae253. doi: 10.1093.
   PubMed     Abstract available
   
   
   April 2024
10. SELVAMANI SP, Khan A, Tay ESE, Garvey M, et al
    Hepatitis B virus and hepatitis C virus affect mitochondrial function through different metabolic pathways, explaining virus-specific clinical features of chronic hepatitis.
    J Infect Dis. 2024 Apr 24:jiae210. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2024
11. WHITTAKER R, Midtbo JE, Klovstad H
    Monitoring progress towards the elimination of hepatitis C as a public health threat in Norway: a modelling study among people who inject drugs and immigrants.
    J Infect Dis. 2024 Mar 27:jiae147. doi: 10.1093.
    PubMed     Abstract available
    
    
    
12. KAMILI S, Wester C
    Advancing diagnosis of current HCV infection: A key to hepatitis C elimination in the United States.
    J Infect Dis. 2024 Mar 11:jiae127. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. ASLANIKASHVILI A, Rylander C, Manjavidze T, Gamkrelidze A, et al
    Relationship between hepatitis C infection and treatment status and COVID-19-related hospitalizations in Georgia.
    J Infect Dis. 2024 Mar 1:jiae103. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
14. TU T, Ajoyan H, Nur Umami R, Veeraraghavan V, et al
    Inhibition of cellular factor TM6SF2 suppresses secretion pathways of Hepatitis B, Hepatitis C and Hepatitis D viruses.
    J Infect Dis. 2024 Feb 26:jiae098. doi: 10.1093.
    PubMed     Abstract available
    
    
    
15. COLLAZOS J, Asensi V
    Non-invasive liver fibrosis markers in the evaluation of fibrosis regression after direct-acting antiviral (DAA) therapy.
    J Infect Dis. 2024 Feb 23:jiae095. doi: 10.1093.
    PubMed    
    
    
    October 2023
16. IVANOVA REIPOLD E, Shilton S, Donolato M, Fernandez Suarez M, et al
    Molecular point of care testing for hepatitis C: available technologies, pipeline and promising future directions.
    J Infect Dis. 2023 Oct 28:jiad463. doi: 10.1093.
    PubMed     Abstract available
    
    
    
17. FELD JJ
    What is needed to move toward single-step diagnosis of current HCV infection?
    J Infect Dis. 2023 Oct 13:jiad453. doi: 10.1093.
    PubMed     Abstract available
    
    
    
18. FALADE-NWULIA O, Lesko CR, Fojo AT, Keruly JC, et al
    Hepatitis C treatment in people living with HIV: Potential to eliminate disease and disparity.
    J Infect Dis. 2023 Oct 5:jiad433. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
19. FRICKER GP, Ghany MG, Mera J, Pinsky BA, et al
    Tools Needed to Support Same-day Diagnosis and Treatment of Current Hepatitis C Infection.
    J Infect Dis. 2023 Sep 22:jiad177. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. CARTWRIGHT EJ, Patel PR
    Opportunities for enhanced prevention and control of hepatitis C through improved screening and testing efforts.
    J Infect Dis. 2023 Sep 22:jiad199. doi: 10.1093.
    PubMed     Abstract available
    
    
    
21. JOHNSON LN, Gaynor AM, Wroblewski K, Buss SN, et al
    Maximizing Reflexive HCV RNA Testing of HCV Antibody-Reactive Samples Within United States Public Health Laboratories.
    J Infect Dis. 2023 Sep 22:jiad191. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. TERRAULT N
    Down-Classification of Hepatitis C Virus Diagnostics: Implications for Screening and Diagnosis.
    J Infect Dis. 2023 Sep 22:jiad299. doi: 10.1093.
    PubMed     Abstract available
    
    
    
23. PAGE K, Feinberg J
    What Hepatitis C (HCV) diagnostic tools are needed to advance diagnosis of current HCV infection in outreach settings and in a non-clinical setting?
    J Infect Dis. 2023 Sep 22:jiad269. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. HANDANAGIC S, Shadaker S, Drobeniuc J, Tsereteli M, et al
    Lessons learned from global hepatitis C elimination programs.
    J Infect Dis. 2023 Sep 22:jiad198. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. CHIEN RN, Lu SN, Hui-Min Wu G, Yang WW, et al
    Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
26. KONDILI LA, Craxi L, Nava F, Babudieri S, et al
    From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
27. AARON A, Zhong H, Hiebert L, Zhuo Y, et al
    Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
28. WASITTHANKASEM R, Wanlapakorn N, Pimsing N, Posuwan N, et al
    Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
29. PRZYBYSZEWSKI EM, Chung RT
    Unmet Needs in the Post-Direct-Acting Antiviral Era: Hepatocarcinogenesis After Hepatitis C Virus Eradication.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
30. HUANG CF, Chen GJ, Hung CC, Yu ML, et al
    HCV Microelimination for High-risk Special Populations.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
31. ADDA D, James C, Peck R, Ali M, et al
    The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
32. UMUTESI J, Yu ML, Lesi O, Ward JW, et al
    Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
33. SPAULDING AC, Kennedy SS, Osei J, Sidibeh E, et al
    Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    
34. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available
    
    
    July 2023
35. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    PubMed     Abstract available
    
    
    
36. FIERER DS, Schinkel J
    Redefining the Paradigm: The Role of Sexual Networks and Sexualized Drug Use in the Transmission of HCV Among Men Who Have Sex with Men.
    J Infect Dis. 2023 Jul 24:jiad265. doi: 10.1093.
    PubMed    
    
    
    June 2023
37. ARTENIE A, Stone J, Facente SN, Fraser H, et al
    Impact of HCV Testing and Treatment on HCV Transmission Among Men Who Have Sex With Men and Who Inject Drugs in San Francisco: A Modelling Analysis.
    J Infect Dis. 2023 Jun 24:jiad169. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2023
38. GAMKRELIDZE A, Shadaker S, Tsereteli M, Alkhazashvili M, et al
    Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021.
    J Infect Dis. 2023 Mar 18:jiad064. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.